Unveiling Liquid Gold: Lymph as an HPV Marker in OPSCC to Guide Treatment Decisions
Postoperative lymphatic fluid may better guide future adjuvant therapy decisions due to its proximity to primary lesions and lymph nodes. April 1, 2024 Read the full article in Clinical Cancer Research: https://aacrjournals.org/clincancerres/article-abstract/30/7/1223/741828/Unveiling-Liquid-Gold-Lymph-as-an-HPV-Marker-in
A Liquid Biopsy for Local Recurrences
AACR shared four cutting-edge highlights from the AACR-AHNS conference (July 7-8, 2023), including Droplet Biosciences data presented by co-founder Dr. José Zevallos that shows lymph is superior to plasma at predicting local recurrences. August 3, 2023 Read the full article in Cancer Research Catalyst: The Official Blog of the American Association for Cancer Research:
Droplet Biosciences Releases First Research Data, Demonstrates Lymph Liquid Biopsy‘s Ability to Predict Locoregional Recurrence
Montréal, QC, Canada – July 8, 2023 – Droplet Biosciences, a pioneer in harnessing the power of lymphatic fluid to provide earlier and more sensitive cancer diagnostics, released its initial research data this morning at AACR-AHNS Head and Neck Conference: Innovating through Basic, Clinical and Translational Research. The abstract Detection of minimal residual disease in post-surgical […]
Droplet Biosciences Announces Lymph Diagnostic Platform to Help Prevent Cancer Recurrence
With an $8 million seed investment led by The Engine, Droplet will develop a novel lymph liquid biopsy for earlier, more precise care following surgery. https://www.businesswire.com/news/home/20230316005040/en/Droplet-Biosciences-Announces-Lymph-Diagnostic-Platform-to-Help-Prevent-Cancer-Recurrence CAMBRIDGE, MA – March 16, 2023 – Droplet Biosciences today announced an $8 million seed investment to establish proof of concept for the company’s technology. While the lymphatic system’s […]
Droplet Biosciences Targets Lymph Fluid in New Residual Cancer Detection Strategy
With an $8M seed investment led by The Engine, Droplet will develop a liquid biopsy test using lymphatic fluid rather than blood plasma as a source for detecting cancer-associated DNA alterations. March 16, 2023 Read the full article on GenomeWeb: https://www.genomeweb.com/cancer/droplet-biosciences-targets-lymph-fluid-new-residual-cancer-detection-strategy#.ZBMW5-zMKrc